Anne Guiochon-Mantel

Anne Guiochon-Mantel

Auto-generated profile, based on publicly available information

Anne Guiochon-Mantel

Molecular Genetics Pharmacogenomics and Hormonology Department, hôpital Bicêtre, Le Kremlin-Bicêtre, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2007 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
FBFranck Bourdeaut
Franck Bourdeaut
AGAnne Guiochon‐Mantel
Anne Guiochon‐Mantel
MFMonique Fabre
Monique Fabre
HMHélène Martelli
Hélène Martelli
CPCatherine Patte
Catherine Patte
EJEmmanuel Jacquemin
Emmanuel Jacquemin

3 April 2019 in Amyloid
Verified
Journal Article
Closed access
SHStéphanie Hayek
Stéphanie Hayek
CAClovis Adam
Clovis Adam
DADavid Adams
David Adams
CCCécile Cauquil
Cécile Cauquil
EBEmmanuel Barreau
Emmanuel Barreau
ARAntoine Rousseau
Antoine Rousseau
(2019). Conjunctival lymphangiectasia: a novel ocular manifestation of hereditary transthyretin amyloidosis. Amyloid. Ahead of Print.

1 June 2020 in Epidemiology and Health
Verified
Journal Article
Open access
PDF file
NLNasser Laouali
Nasser Laouali
SBSylvie Brailly-Tabard
Sylvie Brailly-Tabard
CHCatherine Helmer
Catherine Helmer
MAMarie-Laure Ancelin
Marie-Laure Ancelin
CTChristophe Tzourio
Christophe Tzourio
MCMarianne Canonico
Marianne Canonico
Previous studies yielded controversial findings on the association of testosterone with mortality in older men. Heterogeneity might be partially explained by comorbidities and the presence of metabolic syndrome, and differential associations according to causes of death. We used data from a random subsample of the Three-City study (3C) in which hormones were measured in 338 men ≥65 years without metabolic syndrome, followed-up during 12 years. Vital status was determined for all participants from different sources. We used inverse-probability-weighted Cox regression to estimate hazard ratios (HRs) of cause-specific mortality and 95% confidence intervals (95% CIs). Over the follow-up, 130 men died (30 from cardiovascular disease, 45 from cancer, 55 from other causes). The association of testosterone with mortality showed significant heterogeneity across causes of death (p=0.027 and p=0.022, for total and bioavailable testosterone, respectively). Higher testosterone level was associated with increased cardiovascular mortality (HR for 1-SD increase: 1.86, 95% CI: 1.28-2.71, and 1.50, 95% CI: 1.04-2.17, for total and bioavailable testosterone, respectively). By contrast, there was no significant association of testosterone with mortality from cancer and other causes. Our data suggest that the association of testosterone with mortality in men without metabolic syndrome might be differential according to the cause of death. These findings may explain part of the heterogeneity across studies on the relation between testosterone and mortality.

19 April 2024 in Revue Neurologique
Verified
Journal Article
Closed access
DADavid Adams
David Adams
PCP. Cintas
P. Cintas
GSG. Solé
G. Solé
CTC. Tard
C. Tard
CLC. Labeyrie
C. Labeyrie
SAS. Attarian
S. Attarian

20 September 2012 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
JSJ. Sarfati
J. Sarfati
HBH. Bry
H. Bry
JBJ. Bouligand
J. Bouligand
SBS. Brailly-Tabard
S. Brailly-Tabard
AGA. Guiochon-Mantel
A. Guiochon-Mantel
JYJ. Young
J. Young

1 September 2016 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
LMLuigi Maione
Luigi Maione
ACA. Cartes
A. Cartes
JNJérôme Nevoux
Jérôme Nevoux
AGA. Guiochon-Mantel
A. Guiochon-Mantel
JBJ. Bouligand
J. Bouligand
JYJ. Young
J. Young